The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
The company reported free cash flow of Rs. 2,590 Mn for FY26
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
The platform combines internally developed technologies, strategic partnerships, and external AI capabilities
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches
Subscribe To Our Newsletter & Stay Updated
